- Home
- IBRX vs NICE Comparison
IBRX vs NICE Comparison
Compare IBRX & NICE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | NICE |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | NICE |
|---|---|---|
| Price | $8.58 | $98.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $11.80 | ★ $162.31 |
| AVG Volume (30 Days) | ★ 32.9M | 987.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $680.06 | $9.57 |
| Revenue Next Year | $90.34 | $8.07 |
| P/E Ratio | ★ N/A | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $94.65 |
| 52 Week High | $8.28 | $180.61 |
Technical Indicators
Market Signals| Indicator | IBRX | NICE |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 34.18 |
| Support Level | $5.93 | $94.65 |
| Resistance Level | $7.30 | $115.75 |
| Average True Range (ATR) | 0.81 | 4.54 |
| MACD | -0.00 | -1.45 |
| Stochastic Oscillator | 96.61 | 19.76 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About NICE NICE Ltd
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.